SCHEMBL1709706

SCHEMBL1709706

CCN(CC)CCCS(=O)(=O)N[C@H](CCc1ccccc1)c1nc(-c2ccc(OC)cc2)n(C)n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR Q92847 2/20 0.67
ALDH1A1 P00352 3/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
POLB P06746 1/20 0.40
DRD3 P35462 6/20 0.39
DRD2 P14416 5/20 0.39
USP2 O75604 1/20 0.37
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PDE4D Q08499 2/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP3 P08254 1/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
MLNR O43193 1/20 0.35
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10122295 0.84 GHSR (0.50) GHSRALDH1A1HDAC1HDAC6POLB
SCHEMBL1709737 0.84 GHSR (0.48) GHSRALDH1A1DRD3DRD2USP2
SCHEMBL1709730 0.81 GHSR (0.52) GHSRHDAC1HDAC6DRD3ADRA1A
SCHEMBL1709720 0.81 GHSR (0.52) GHSRHDAC1HDAC6DRD3LMNA
SCHEMBL1709673 0.81 GHSR (0.52) GHSRHDAC1HDAC6DRD3ADRA1A
SCHEMBL1709658 0.80 GHSR (0.51) GHSRALDH1A1HDAC1HDAC6DRD3
SCHEMBL1990385 0.80 GHSR (1.00) GHSRALDH1A1HDAC1HDAC6POLB
SCHEMBL1989714 0.79 GHSR (0.72) GHSRALDH1A1POLBHTTLMNA
SCHEMBL10121710 0.78 GHSR (0.48) GHSRHDAC1HDAC6POLBLMNA
SCHEMBL1709734 0.78 GHSR (0.49) GHSRHDAC1HDAC6DRD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088747-A1 SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF ELIXIR PHARMACEUTICALS, INC. 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088747-A1 SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF GHSR, GHRHR, STS GHSR 1/4885ALDH1A1 3182/4885HDAC1 803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.